1. Home
  2. KRNY vs SGMT Comparison

KRNY vs SGMT Comparison

Compare KRNY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$9.56

Market Cap

603.5M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$11.08

Market Cap

676.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
SGMT
Founded
1884
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
603.5M
676.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
KRNY
SGMT
Price
$9.56
$11.08
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$9.25
$26.13
AVG Volume (30 Days)
527.5K
865.8K
Earning Date
04-23-2026
05-14-2026
Dividend Yield
5.45%
N/A
EPS Growth
35.71
N/A
EPS
0.57
N/A
Revenue
$2,580,000.00
$2,000,000.00
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
N/A
P/E Ratio
$16.81
N/A
Revenue Growth
36.00
N/A
52 Week Low
$6.23
$4.50
52 Week High
$10.24
$11.45

Technical Indicators

Market Signals
Indicator
KRNY
SGMT
Relative Strength Index (RSI) 41.78 61.34
Support Level $9.43 $6.60
Resistance Level $9.74 $11.30
Average True Range (ATR) 0.21 0.55
MACD -0.06 -0.07
Stochastic Oscillator 12.66 77.98

Price Performance

Historical Comparison
KRNY
SGMT

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: